ACCP

2024 Annual Meeting of the American College of Clinical Pharmacology® - The Premier Clinical Pharmacology Educational & Scientific Meeting

Retrieved on: 
화요일, 4월 23, 2024
ACCME, Accreditation Council, American College, CME, Trainee, ACPE, Student, PBPK, Health, Accreditation, Drug development, Continuing medical education, ACCP, Pharmacology, Nursing

ASHBURN, Va. , April 23, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) is pleased to announce its 2024 ACCP Annual Meeting (#2024ACCP) will be held September 8 – 10, 2024. We encourage you to join us for this transformative educational and scientific event! ACCP provides healthcare professionals and scientists with a forum to exchange knowledge and ideas that promote and expand the value of clinical pharmacology in healthcare and drug development.

Key Points: 
  • ASHBURN, Va. , April 23, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) is pleased to announce its 2024 ACCP Annual Meeting (#2024ACCP) will be held September 8 – 10, 2024.
  • We encourage you to join us for this transformative educational and scientific event!
  • ACCP provides healthcare professionals and scientists with a forum to exchange knowledge and ideas that promote and expand the value of clinical pharmacology in healthcare and drug development.
  • Green, President, ACCP stated, "I am pleased to formally invite you to the 2024ACCP Annual Meeting in Bethesda, MD!

Prescription of Oral Contraceptives by Licensed Pharmacists in the US

Retrieved on: 
월요일, 3월 4, 2024
Combined oral contraceptive pill, Pharmacy, Pharmacology, Woman, OCS, ACCP, Pharmacist, Position paper, Risk, Safety, Health, Contraindication, Pharmacokinetics, American College, Birth, Advantage

ASHBURN, Va., March 4, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled "Prescription of Oral Contraceptives by Licensed Pharmacists in the US" .

Key Points: 
  • ASHBURN, Va., March 4, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled "Prescription of Oral Contraceptives by Licensed Pharmacists in the US" .
  • Oral contraceptives (OCs) provide a highly effective method of contraception if adherence is maintained; OCs have been prescribed in the US and globally for several decades.
  • The American College of Clinical Pharmacology (ACCP) strongly recommends the enactment of an initiative that permits licensed US pharmacists to prescribe OCs on a national basis.
  • This supports OCs as suitable for prescription by licensed pharmacists at a national level.

ACCP Position Statement: "Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action"

Retrieved on: 
목요일, 1월 11, 2024
Obesity, Patient, Drug development, Paper, Pharmacology, Map, Risk, Position paper, Journal, ACCP, Therapy, American College, Prevalence

ASHBURN, Va., Jan. 11, 2024 /PRNewswire/ -- A recent Position Paper from the American College of Clinical Pharmacology® (ACCP) entitled " Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action" was published in The Journal of Clinical Pharmacology.

Key Points: 
  • ASHBURN, Va., Jan. 11, 2024 /PRNewswire/ -- A recent Position Paper from the American College of Clinical Pharmacology® (ACCP) entitled " Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action" was published in The Journal of Clinical Pharmacology.
  • Obesity is a national health issue, with a prevalence that has increased steadily in the United States over the past 20 years.
  • This is a concern, as obesity is associated with an increased risk for many other comorbid diseases.
  • This Position Paper calls for actions to enable the inclusion of obese participants in clinical trials during the drug development process.

ACCP Position Statement: "Hydration and Vitamin Infusion Clinics"

Retrieved on: 
금요일, 1월 5, 2024
American College, Position paper, Safety, Vitamin, ACCP, Education

ASHBURN, Va., Jan. 5, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled " Hydration and Vitamin Infusion Clinics ".

Key Points: 
  • ASHBURN, Va., Jan. 5, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled " Hydration and Vitamin Infusion Clinics ".
  • Hydration and vitamin clinics, so-called "drip clinics", offer vitamin infusions (like vitamin B or C) and intravenous hydration cocktails that its proponents, including celebrities, argue have a variety of uses, including relief from sore muscles, possible hangover cure, treating jet lag, and a general improvement in overall well-being.
  • Often these infusions are administered outside of a hospital or clinic setting and, sometimes, not under medical supervision using vitamins of unknown quality, preparation, and purity.
  • Currently these "infusion clinics" are largely unregulated, highlighting the need for greater regulatory oversight.

Dr. John N. van den Anker Named New Editor-in-Chief of The Journal of Clinical Pharmacology

Retrieved on: 
목요일, 1월 4, 2024
Doctor of Pharmacy, FCP, Child, JCP, Publishing, MD, Doctor of Philosophy, ACCP, Children's National Hospital, FAAP, American College, Journal, Pharmacology, Nursing

ASHBURN, Va., Jan. 4, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) proudly announces the appointment of Dr. John N. van den Anker, MD, PhD, FAAP, FCP, as the new Editor-in-Chief of The Journal of Clinical Pharmacology (JCP).

Key Points: 
  • ASHBURN, Va., Jan. 4, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) proudly announces the appointment of Dr. John N. van den Anker, MD, PhD, FAAP, FCP, as the new Editor-in-Chief of The Journal of Clinical Pharmacology (JCP).
  • A distinguished neonatal and pediatric clinical pharmacologist, Dr. van den Anker currently holds the Evan and Cindy Jones Endowed Chair of Pediatric Clinical Pharmacology at Children's National Hospital in Washington, DC.
  • With a decade of service on the JCP Editorial Board and an extensive record of publishing, Dr. van den Anker brings unparalleled expertise to his new role.
  • ACCP invites members and the scientific community to welcome Dr. John N. van den Anker and his team, marking a pivotal moment in the ongoing success of The Journal of Clinical Pharmacology.

StopAfib.org Applauds New Atrial Fibrillation Guidelines to Improve Patient Care

Retrieved on: 
수요일, 12월 13, 2023
Atrial fibrillation, Organization, Disease, AHA, ACC, Diagnosis, Patient, ACCP, American College, Heart Rhythm Society, HRS, Writing, Atrium (heart), Quality of life, American Heart Association, Ventricular fibrillation

In addition to the many healthcare professionals who played a part in developing these guidelines, afib patients were also involved in the writing and peer review processes.

Key Points: 
  • In addition to the many healthcare professionals who played a part in developing these guidelines, afib patients were also involved in the writing and peer review processes.
  • StopAfib.org is immensely grateful to these organizations for including the patient perspective, thereby working to address the needs and concerns of patients.
  • These guidelines will help improve care for afib patients, and emphasizing shared decision-making will help patients feel seen and heard," said Mellanie True Hills, Founder and CEO of StopAfib.org.
  • "As an afib patient, I know that collaboration with the healthcare team is vital for getting the best possible care.

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
화요일, 11월 7, 2023
Type, FDA, American College, Phase II, AD, Food, ALEC, CSF, ACCP, Frontotemporal dementia, European Medicines Agency, Microglia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Arnon Rosenthal, Disease, Partnership, EMA, GSK, Blood, TREM2, Alector, AbbVie, Safety, Total, Investment, FTD, Granulin, Pharmaceutical industry, Vaccine, Rare-earth element

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported third quarter 2023 financial results and recent portfolio and business updates. As of September 30, 2023, Alector’s cash, cash equivalents and investments totaled $588.9 million.

Key Points: 
  • “We’ve made significant clinical advancements in our late-stage immuno-neurology programs in the second half of 2023,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.
  • In September 2023, Alector completed enrollment in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial, with data anticipated in the fourth quarter of 2024.
  • Collaboration revenue for the quarter ended September 30, 2023, was $9.1 million, compared to $14.9 million for the same period in 2022.
  • Total research and development expenses for the quarter ended September 30, 2023, were $46.3 million, compared to $48.3 million for the quarter ended September 30, 2022.

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

Retrieved on: 
수요일, 8월 30, 2023
Biotechnology, Health, Clinical Trials, ACCP, American College of Clinical Pharmacology, Development of the human body, DSM-IV codes, Medication, Plasma, Pharmacokinetics, Annual general meeting, IEC, Prolactin, Seizure, American College, QEEG, Pharmaceutical industry, Safety, Pharmacology

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting.
  • Title: The PACIFIC Study: A Phase 1b/2a Study to Investigate the Safety, Tolerability, Pharmacology, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies (#758)
    Title: Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist (#754)
    Title: Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist (#749)
    Title: A Phase 1 Study of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma and CSF Pharmacokinetics, and QEEG Changes Reflecting Receptor Engagement (#060)

Alector Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
목요일, 8월 3, 2023
Amyloid-related imaging abnormalities, ACCP, Alector, European Medicines Agency, GPNMB, Interest, Plasma, AAIC, Journal, TREM2, Patent, Investment, Patient, European Patent Office, Arnon Rosenthal, American College, Disease, Maintenance, Contra, EMA, HIV disease progression rates, Manuscript, CSF, FDA, Conference, Total, Safety, GSK, Biomarker, ARIA, PIN, Translational medicine, Amyloid, SAN, Blood, Frontotemporal dementia, Clutch (eggs), Webcast, Microglia, American College of Clinical Pharmacology, Journal of Translational Medicine, Type, MRI, European Patent Convention, Poster, ALEC, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, Food, Pharmaceutical industry, Vaccine, Medical imaging, Research

ET / 1:30 p.m. PT

Key Points: 
  • ET / 1:30 p.m. PT
    SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported second quarter 2023 financial results and recent portfolio and business updates.
  • Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC) in July 2023.
  • In the second quarter of 2023, the U.S. Patent and Trademark Office issued patents covering methods of treatment using AL002.
  • Alector’s management team will host a conference call discussing Alector’s results for the second quarter of 2023 and provide a business update.

Mediaplanet and Tony Robbins Help Small Businesses With Tips to Succeed

Retrieved on: 
화요일, 6월 27, 2023
ACCP, Small business, NGLCC, NASE, IAB, USA Today, Social media, Chamber of commerce, Commerce, Video game, Humana

NEW YORK, June 27, 2023 /PRNewswire-PRWeb/ -- Mediaplanet today announces the launch of this June's edition of "Small Business". This campaign will give insight to those running a small business on how they can navigate the market as well as tips on how they themselves can improve along with their business.

Key Points: 
  • NEW YORK, June 27, 2023 /PRNewswire-PRWeb/ -- Mediaplanet today announces the launch of this June's edition of "Small Business".
  • The latest statistics show that there are 33.2 million small businesses in the US, which account for 99.9 percent of all US businesses.
  • These small businesses may be mom-and-pop shops or larger enterprise operations that single-handedly affect entire communities of any size.
  • With the falling economy and issues with major banks rising, it is important now to showcase resources to help small businesses not just survive but thrive.